X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4079) 4079
Newsletter (51) 51
Magazine Article (28) 28
Newspaper Article (24) 24
Dissertation (8) 8
Book Chapter (5) 5
Streaming Video (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lansoprazole (3717) 3717
humans (2727) 2727
male (1828) 1828
female (1603) 1603
omeprazole (1527) 1527
proton pump inhibitors (1490) 1490
2-pyridinylmethylsulfinylbenzimidazoles (1411) 1411
omeprazole - analogs & derivatives (1364) 1364
middle aged (1294) 1294
gastroenterology & hepatology (1291) 1291
adult (1254) 1254
pharmacology & pharmacy (1111) 1111
aged (874) 874
omeprazole - therapeutic use (822) 822
helicobacter infections - drug therapy (805) 805
helicobacter pylori (802) 802
anti-ulcer agents - therapeutic use (769) 769
treatment outcome (665) 665
drug therapy, combination (587) 587
rabeprazole (511) 511
omeprazole - administration & dosage (497) 497
pantoprazole (486) 486
proton pump inhibitor (477) 477
gastroesophageal reflux - drug therapy (457) 457
anti-ulcer agents - administration & dosage (442) 442
omeprazole - pharmacology (388) 388
pharmacokinetics (382) 382
infection (378) 378
animals (352) 352
esomeprazole (341) 341
helicobacter pylori - drug effects (338) 338
anti-bacterial agents - therapeutic use (328) 328
eradication (328) 328
amoxicillin - therapeutic use (327) 327
adolescent (325) 325
double-blind method (308) 308
prospective studies (308) 308
gastroesophageal reflux (307) 307
therapy (306) 306
clarithromycin - therapeutic use (298) 298
proton pump inhibitors - therapeutic use (292) 292
anti-ulcer agents - pharmacology (282) 282
ranitidine (282) 282
clarithromycin (279) 279
efficacy (276) 276
amoxicillin (275) 275
double-blind (269) 269
omeprazole - adverse effects (269) 269
aged, 80 and over (265) 265
medicine & public health (264) 264
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (260) 260
drug administration schedule (260) 260
dose-response relationship, drug (259) 259
time factors (257) 257
amoxicillin - administration & dosage (256) 256
hydrogen-ion concentration (256) 256
gastroesophageal-reflux disease (246) 246
medicine, general & internal (243) 243
anti-ulcer agents - adverse effects (239) 239
clarithromycin - administration & dosage (238) 238
triple therapy (236) 236
proton pump inhibitors - administration & dosage (231) 231
anti-bacterial agents - administration & dosage (223) 223
drug interactions (223) 223
duodenal-ulcer (217) 217
management (215) 215
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (212) 212
enzyme inhibitors - therapeutic use (211) 211
gastroesophageal reflux disease (210) 210
peptic ulcer - drug therapy (209) 209
cross-over studies (203) 203
esophagitis (202) 202
cytochrome p-450 cyp2c19 (191) 191
helicobacter infections - complications (188) 188
rats (187) 187
young adult (187) 187
disease (183) 183
omeprazole - pharmacokinetics (182) 182
proton pump inhibitors - adverse effects (181) 181
stomach ulcer - drug therapy (177) 177
administration, oral (176) 176
duodenal ulcer - drug therapy (174) 174
helicobacter infections - microbiology (172) 172
helicobacter pylori - isolation & purification (171) 171
proton pump inhibitors - pharmacology (168) 168
gastroenterology (160) 160
cyp2c19 (159) 159
internal medicine (159) 159
helicobacter-pylori (158) 158
drug therapy (157) 157
metronidazole (156) 156
follow-up studies (155) 155
genotype (154) 154
care and treatment (152) 152
enzyme inhibitors - pharmacology (151) 151
gastric acid - secretion (151) 151
esophagitis, peptic - drug therapy (149) 149
intragastric ph (147) 147
recurrence (147) 147
erosive esophagitis (146) 146
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3888) 3888
Japanese (189) 189
French (69) 69
German (60) 60
Spanish (46) 46
Korean (19) 19
Russian (18) 18
Chinese (10) 10
Portuguese (8) 8
Turkish (6) 6
Italian (5) 5
Czech (4) 4
Ukrainian (4) 4
Dutch (3) 3
Hungarian (3) 3
Polish (3) 3
Norwegian (2) 2
Swedish (2) 2
Croatian (1) 1
Danish (1) 1
Finnish (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
Gut, ISSN 0017-5749, 02/2020, Volume 69, Issue 2, pp. 224 - 230
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently,... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 68, Issue 16, pp. 1756 - 1764
Journal Article
Journal Article
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 2017, Volume 145, Issue C, pp. 178 - 191
[Display omitted] Cytochrome P450 1A2 (CYP1A2) is one of the most abundant and important drug metabolizing enzymes in human liver. However, little is known... 
MicroRNA | Toxicity | hsa-miR-132-5p | Drug metabolizing enzymes | CYP1A2 | CANCER PATIENTS | CYTOCHROME-P450 1A2 | FLUTAMIDE | PROLIFERATION | BREAST | HUMAN LIVER-CELLS | METABOLISM | PHARMACOLOGY & PHARMACY | CARCINOMA | DRUG-INTERACTION | Gene Expression Regulation, Enzymologic - drug effects | Lansoprazole - pharmacokinetics | Proton Pump Inhibitors - pharmacology | Humans | MicroRNAs - metabolism | Gene Expression Regulation, Enzymologic - physiology | RNA, Messenger - metabolism | Antineoplastic Agents, Hormonal - pharmacokinetics | Proton Pump Inhibitors - administration & dosage | Computer Simulation | Cytochrome P-450 CYP1A2 - genetics | Lansoprazole - administration & dosage | Cell Line | Antineoplastic Agents, Hormonal - pharmacology | RNA Processing, Post-Transcriptional - drug effects | Antineoplastic Agents, Hormonal - administration & dosage | RNA, Messenger - genetics | Cell Proliferation - physiology | Cytochrome P-450 CYP1A2 - metabolism | Flutamide - pharmacology | Proton Pump Inhibitors - pharmacokinetics | Lansoprazole - pharmacology | Cell Proliferation - drug effects | MicroRNAs - genetics | Flutamide - administration & dosage | Flutamide - pharmacokinetics | Liver cancer | Epigenetic inheritance | Liver | Genomics | Cytochrome P-450 | Genetic research | Genetic transcription | Health savings accounts | Index Medicus
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 10/2013, Volume 48, Issue 10, pp. 1128 - 1135
Journal Article
Journal Article
Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 11, p. CD006640
Background Tranexamic acid reduces haemorrhage through its antifibrinolytic effects. In a previous version of the present review, we found that tranexamic acid... 
Injections, Intravenous | Administration, Oral | Aluminum Hydroxide | Gastrointestinal Hemorrhage | Gastroenterology & hepatology | Anti‐Ulcer Agents | Cimetidine | Endoscopy, Gastrointestinal | DUODENUM | Pharmacology | Tranexamic Acid | Ulcer (Complicated) | Magnesium Hydroxide | Randomized Controlled Trials as Topic | Antifibrinolytic Agents | Treatment | Other bowel disorders | Magnesium | Medicine General & Introductory Medical Sciences | Haemorrhage | Ulcers (gastric or duodenal) | Drug Combinations | Lansoprazole | STOMACH | Lansoprazole [therapeutic use] | MORTALITY | HEMORRHAGE | Humans | METAANALYSES | MEDICINE, GENERAL & INTERNAL | THERAPY | INHIBITION | Anti-Ulcer Agents [therapeutic use] | Cimetidine [therapeutic use] | BLOOD-TRANSFUSION | PEPTIC-ULCER | MANAGEMENT | THROMBOSIS | Aluminum Hydroxide [therapeutic use] | Tranexamic Acid [adverse effects; therapeutic use] | Magnesium [therapeutic use] | Gastrointestinal Hemorrhage [drug therapy; mortality] | Antifibrinolytic Agents [adverse effects; therapeutic use] | CONSENSUS RECOMMENDATIONS | Magnesium Hydroxide [therapeutic use] | Cimetidine - therapeutic use | Anti-Ulcer Agents - therapeutic use | Antifibrinolytic Agents - therapeutic use | Aluminum Hydroxide - therapeutic use | Antifibrinolytic Agents - adverse effects | Gastrointestinal Hemorrhage - mortality | Tranexamic Acid - therapeutic use | Tranexamic Acid - adverse effects | Magnesium - therapeutic use | Magnesium Hydroxide - therapeutic use | Gastrointestinal Hemorrhage - drug therapy | Lansoprazole - therapeutic use
Journal Article